Will Herrington
willkidney.bsky.social
Will Herrington
@willkidney.bsky.social
Kidney doctor and professor of clinical trials and epidemiology of kidney disease at CTSU, University of Oxford. EMPA-KIDNEY & EASi-KIDNEY CI. Needs to be large & randomized (or a bike!)
2025 @thelancet.com #CKD seminar out! Read it for latest evidence on how to manage what is projected to become a top
5 leading cause of death globally by 2050 (read it so in 25years’ time that does not happen…):

www.sciencedirect.com/science/arti...
November 26, 2025 at 4:02 AM
Important link to a @jama.com collaborative meta-analysis should you need to know more about the effects of #SGLT2i on kidney, CV, mortality and hospitalization outcomes in patients with and without diabetes, and at low levels of albuminuria: jamanetwork.com/journals/jam...
November 26, 2025 at 3:43 AM
Reposted by Will Herrington
🎉Over 300 sites are now collaborating in the EASi-KIDNEY trial!

📉EASi-KIDNEY will investigate whether a novel treatment can help slow the progression of chronic kidney disease (CKD) ➡️ buff.ly/PXTVVeE
November 25, 2025 at 8:43 AM
Almost all u need 2 know about the remarkable clinical effects of #SGLT2i on the kidney in a wide ranging IPD metaanalysis (covers effects by albuminuria, predicted eGFR dip and novel exploratory eGFR slope methods). Please do read it! @oxpop.bsky.social @martinlandray.bsky.social
October 12, 2025 at 8:46 PM
3000th #EASi-KIDNEY pt screened. The aim is to accelerate & maximize recruited b4 Xmas 🎄 💝 Final target=11000 randomized! Nephrology showing we can recruit #CKD rapidly & at scale. Thank you for everyone’s perseverance during setup. 🤩 ⁦‪⁦‪@Oxford_NDPH‬⁩ ⁦‪@DCRINews‬⁩
August 20, 2025 at 6:31 AM
We don’t want travel insurance companies to punish trial volunteers - the treatments we all rely upon are thanks to volunteers from the past, present and future. Worth everyone subsiding. Agreed? If so, please sign below….! petition.parliament.uk/petitions/72...
Petition: Ban travel insurance premium hikes & refusals for people in clinical trials
Ban travel insurance companies vastly increasing premiums, or refusal to cover people who partake in clinical trials, which may make it impossible for them to travel without resulting in substantial a...
petition.parliament.uk
July 21, 2025 at 1:37 PM
Reposted by Will Herrington
Collider bias affects genome-wide association studies (GWAS) of disease progression phenotypes. @willkidney.bsky.social ney.bsky.social
This study reports a method to reduce this bias. Find out more ⬇️
www.nature.com/articles/s41...
An application of the MR-Horse method to reduce selection bias in genome-wide association studies of disease progression - European Journal of Human Genetics
European Journal of Human Genetics - An application of the MR-Horse method to reduce selection bias in genome-wide association studies of disease progression
www.nature.com
June 18, 2025 at 5:06 AM
@ukkidney.org anaemia in #CKD guidelines head-to-head with @kdigo.org draft statements at #UKKW25 debate in Bournemouth. Exact Hb threshold may be as low as 9 g/dL (or as high as 10.5!) DW vs SB.
June 12, 2025 at 9:24 AM
Reposted by Will Herrington
🌍 History made! For the first time, kidney care is on the global health agenda. #WHA78 adopted a landmark resolution recognizing kidney health in the fight against #NCDs.

👏 Thanks to Guatemala and the global kidney community for making this possible!

#KidneyHealthMatters
May 23, 2025 at 2:28 PM
In 1978, the idea that large randomized trials was born in this important Richard Peto paper….Rory Collins telling the story of CTSU @oxpop.bsky.social (following Rona Smith’s talk describing large dialysis trial in progress 47 years later!)
May 16, 2025 at 8:30 AM
#EASi-KIDNEY recruitment building globally! Nephrology aiming to show the world we can complete mega-trials (target 11,000 recruits). @oxpop.bsky.social Parminder Judge presenting to the UK collaboration today thanking sites for pushing through the startup processes (more at www.easikidney.org)
May 16, 2025 at 8:27 AM
Interesting preliminary data on SGLT2i in ADPKD on background of tolvaptan. Worthy of larger trials….
📖 This weekend don't miss our @kireports.bsky.social #ISNFridaySelection: Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan www.kireports.org/ar...
May 13, 2025 at 3:47 AM